Section Arrow
NBIX.NASDAQ
- Neurocrine Biosciences
Quotes are at least 15-min delayed:2025/09/14 12:25 EDT
Regular Hours
Last
 141.87
-1.73 (-1.20%)
Day High 
144.04 
Prev. Close
143.6 
1-M High
145.79 
Volume 
485.69K 
Bid
122.5
Ask
150
Day Low
141.73 
Open
142.44 
1-M Low
124.36 
Market Cap 
14.24B 
Currency USD 
P/E 42.49 
%Yield -- 
10-SMA 141.39 
20-SMA 137.85 
50-SMA 133.67 
52-W High 154.61 
52-W Low 84.23 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
3.38/6.21
Enterprise Value
14.70B
Balance Sheet
Book Value Per Share
27.17
Cash Flow
Cash Flow Yield
0.04
Income Statement
Total Revenue
2.36B
Operating Revenue Per Share
17.99
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TLRYTilray Brands1.12+0.06+5.66%-- 
IXHLIncannex Healthcare0.5475+0.0175+3.30%-- 
CGCCanopy Growth Corp1.37-0.02-1.44%-- 
VTRSViatris9.96-0.21-2.06%227.2PE
TEVATeva Pharmaceutical Industries Limited19.93+0.04+0.20%-- 
Quotes are at least 15-min delayed:2025/09/14 12:25 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.